Lantus  (insulin glargine [rDNA] injection) 100 units per ml (U100) 


Manufacturer: Aventis Pharmaceuticals

Indication(s):  Lantus is indicated for once-daily subcutaneous administration at bedtime in the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.

Administration:  Lantus should be administered to patients >6 years of age subcutaneously once daily at bedtime.  Injection sites within an injection area (abdomen, thigh or deltoid) must be rotated from one injection to the next.

Pharmacology:  The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analogs lower blood glucose levels by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis in the adipocyte, inhibits proteolysis, and enhances protein synthesis.

WebRx Editorial Notes:  Mixing and diluting. Lantus must not be diluted or mixed with any other insulin or solution.  Lantus must only be used if the solution is clear and colorless with no particles visible.  If refrigeration is not possible, the 10 mL vial or cartridge of Lantus in use can be kept unrefrigerated for up to 28 days away from direct heat and light, as long as the temperature is not greater than 86°F (30°C).  Unrefrigerated 10 mL vials and cartridges must be used within the 28-day period or they must be discarded.  Once a cartridge is placed in an OptiPen One, it should not be put in the refrigerator. 

©2002 WebRx Pharmacy Palace